Sponsors (7)
The resolution raises the profile of rare diseases and underscores research and regulatory pathways that could aid future treatments, but it provides no funding or immediate policy changes and may create unmet expectations while diverting attention from access and affordability.
People with rare diseases and their families gain greater visibility through official findings, increasing public and policymaker attention to their needs.
Patients with rare diseases benefit from the resolution's emphasis on FDA regulatory programs and orphan drug approvals, which highlights pathways that can speed development and eventual access to treatments.
Researchers and patients may gain stronger justification for continued or increased NIH research funding into rare-disease treatments because the resolution recognizes NIH support.
People with rare diseases and their families receive no new funding or specific policy changes from the resolution, so they are unlikely to see immediate improvements in diagnosis, treatment, or costs.
Patients and the public may develop unrealistic expectations about quick treatment availability because the resolution highlights FDA approvals even though most rare diseases still lack approved therapies.
Emphasizing research and drug approvals could shift attention and resources toward long-term development rather than near-term issues like diagnostics, affordability, and access for low-income patients.
Based on analysis of 2 sections of legislative text.
Records findings on rare diseases, recognizes Rare Disease Day, and highlights prevalence, regulatory milestones, and treatment gaps; it is a nonbinding awareness resolution.
Official title: Designating February 27, 2025, as "Rare Disease Day".
Introduced February 27, 2025 by John A. Barrasso · Last progress February 27, 2025
Recognizes Rare Disease Day and sets out congressional findings about rare diseases in the United States. The resolution defines a rare disease (affecting fewer than 200,000 people), summarizes prevalence and impacts (over 30 million Americans affected, many children), notes scientific and regulatory milestones (Orphan Drug Act anniversary, FDA approvals), and highlights gaps in treatments, diagnostics, financing, and access for patients and families.